Strong Product Portfolio Nabriva offers innovative antibiotics, including FDA-approved Xenleta and the pipeline asset Contepo, targeting serious infections such as cUTIs, positioning the company well for expanding sales into antimicrobial therapies and hospital accounts.

Strategic Partnerships The company's collaborations with Erkim Ilac and Merck for distribution and marketing suggest opportunities to leverage these relationships to increase sales via expanded geographical reach and new healthcare providers.

Recent Asset Sales Nabriva has divested some of its assets, such as Contepo rights in North America, which indicates potential focus on core markets; remaining assets and pipeline could offer new prospects for targeted sales strategies.

Financial Capacity With revenue between $10 million and $50 million and funding of $92 million, Nabriva has the financial stability to invest in sales expansion, customer outreach, and marketing initiatives for its key products.

Global Presence Operating in multiple regions including the US, Ireland, Austria, and China, Nabriva presents opportunities for international sales growth, especially through its partnership networks and distribution agreements.